If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Beatrice Dozin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
Chondrocytes Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Chondrogenesis Medicine & Life Sciences
Lipocalins Medicine & Life Sciences
Cartilage Medicine & Life Sciences
Thyroid Hormones Medicine & Life Sciences
Sentinel Lymph Node Biopsy Medicine & Life Sciences
Messenger RNA Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1985 2018

  • 3136 Citations
  • 26 h-Index
  • 76 Article
  • 1 Comment/debate
  • 1 Letter
1 Citation (Scopus)
Conflict of Interest
Melanoma
Survival
Italy
Genes

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Queirolo, P., Dozin, B., Morabito, A., Banelli, B., Carosio, R., Fontana, V., Ferrucci, P. F., Martinoli, C., Cocorocchio, E., Ascierto, P. A., Madonna, G., Simeone, E., De Galitiis, F., Antonini Cappellini, G. C., Marchetti, P., Guida, M., Tommasi, S., Ghilardi, L., Merelli, B., Fava, P. & 7 others, Osella-Abate, S., Guidoboni, M., Romani, M., Ferone, D., Spagnolo, F., Pistillo, M. P. & (IMI), I. M. I., 2018, In : European journal of cancer. 97, p. 59-61 3 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Italian Melanoma Intergroup (IMI), Jul 1 2018, In : European Journal of Cancer. 97, p. 59-61 3 p.

Research output: Contribution to journalLetter

4 Citations (Scopus)

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

on behalf of the Italian Melanoma Intergroup (IMI), Jan 1 2018, (Accepted/In press) In : Cancer Immunology, Immunotherapy.

Research output: Contribution to journalArticle

Melanoma
Biomarkers
ipilimumab
Survival Analysis
Serum
166 Citations (Scopus)

20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years

Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., Hayes, D. F., EBCTCG, Bighin, C., Bruzzi, P., Del Mastro, L., Dozin, B., Pronzato, P. & Sertoli, M. R., Nov 9 2017, In : New England Journal of Medicine. 377, 19, p. 1836-1846 11 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Recurrence
Therapeutics
Estrogen Receptors
Neoplasms